 |
|
Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy
Joo-Hark Yi, Sang-Woong Han, Wan-Young Kim, Jin Kim, Moon-Hyang Park
Korean J Intern Med. 2018;33(4):763-773. Published online 2017 Feb 15 DOI: https://doi.org/10.3904/kjim.2016.097
|
|
Citations to this article as recorded by
 Long-term oral administration of Kelisha capsule does not cause hepatorenal toxicity in rats
Suyan Liu, Yong Zhao, Chunying Li, Yan Yi, Yushi Zhang, Jingzhuo Tian, Jiayin Han, Chen Pan, Xiao Lu, Yan Su, Lianmei Wang, Chenyue Liu, Jing Meng, Aihua Liang
Journal of Ethnopharmacology.2024; 332: 118320. CrossRef Evaluation and management of hypernatremia in adults: clinical perspectives
Giae Yun, Seon Ha Baek, Sejoong Kim
The Korean Journal of Internal Medicine.2023; 38(3): 290. CrossRef Nephrotoxicity of Herbal Medicine and Its Prevention
Xiaofen Xu, Ruyi Zhu, Jialiang Ying, Mengting Zhao, Xin Wu, Gang Cao, Kuilong Wang
Frontiers in Pharmacology.2020;[Epub] CrossRef Aristolochic acid I aggravates renal injury by activating the C3a/C3aR complement system
Jing Ye, Zhizhi Qian, Mei Xue, Yamin Liu, Sirui Zhu, Yu Li, Xiaoli Liu, Danhong Cai, Jia Rui, Liang Zhang
Toxicology Letters.2019; 312: 118. CrossRef Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms
Jiayin Han, Zhong Xian, Yushi Zhang, Jing Liu, Aihua Liang
Frontiers in Pharmacology.2019;[Epub] CrossRef
|